




FIG. 1




FIG. 2

## Arm A:

- ◆ Induction (3-week cycle - 21 days): Cycles 1 to 4
  - Carboplatin Day 1: area under the curve (AUC) 5 mg/mL/min intravenous (IV)
  - Etoposide Days 1, 2, 3: 100 mg/m<sup>2</sup> IV
  - BMS-986012 Day 1: 420 mg IV
  - Nivolumab Day 1: 360 mg IV
- ◆ Maintenance (4-week cycle - 28 days): Cycle 5 and beyond
  - BMS-986012 Day 1: 560 mg IV
  - Nivolumab Day 1: 480 mg IV

## Arm B

- ◆ Induction (3-week cycle - 21 days): Cycles 1 to 4
  - Carboplatin Day 1: AUC 5 mg/mL/min IV
  - Etoposide Days 1, 2, 3: 100 mg/m<sup>2</sup> IV
  - Nivolumab Day 1: 360 mg IV
- ◆ Maintenance (4-week cycle -28 days): Cycle 5 and beyond:
  - Nivolumab Day 1: 480 mg IV

FIG. 3A

| Procedure<br>Study Cycle      | Cycles 1 and 2 (N = 21 days) |                     |                     |                      | Cycles 3 and 4<br>(N = 21 days) | Cycles 5 and<br>beyond<br>(N = 28 days) | EOT <sup>a</sup> | Notes                              |
|-------------------------------|------------------------------|---------------------|---------------------|----------------------|---------------------------------|-----------------------------------------|------------------|------------------------------------|
|                               | D1<br>(± 3<br>days)          | D2<br>(± 3<br>days) | D8<br>(± 3<br>days) | D15<br>(± 3<br>days) |                                 |                                         |                  |                                    |
| Study Cycle Day               |                              |                     |                     |                      | D1<br>(± 3 days)                | D1<br>(± 3 days)                        |                  |                                    |
| Carboplatin<br>Administration | X                            |                     |                     |                      | X                               |                                         |                  |                                    |
| Etoposide Administration      | Days 1, 2,<br>and 3          |                     |                     |                      | Days 1, 2,<br>and 3             |                                         |                  |                                    |
| Nivolumab<br>Administration   | X                            |                     |                     |                      | X                               | X                                       |                  |                                    |
| BMS-986012<br>Administration  | X                            |                     |                     |                      | X                               | X                                       |                  | If assigned to treatment<br>Arm A. |

Abbreviations: AE = adverse event; CT = computed tomography; D = Day; EOT = end of treatment;  
MRI = magnetic resonance imaging; PK = pharmacokinetic; WOCBP = woman of childbearing potential.

FIG. 3B